<DOC>
	<DOCNO>NCT00000761</DOCNO>
	<brief_summary>PRIMARY : To determine safety toxicity recombinant interferon gamma-1b ( rIFN-gamma ) HIV-infected child receive ongoing zidovudine ( AZT ) didanosine ( ddI ) therapy . To document HIV-associated defect neutrophil and/or monocyte function improve rIFN-gamma . SECONDARY : To determine whether change CD4 cell count occur assess virologic status effect AZT ddI pharmacokinetics . It likely infant child severely immunocompromised HIV infection would respond immunomodulators augment different portion host defense system . Interferon-gamma show benefit child severely compromise nonspecific immunity may thus benefit HIV infection .</brief_summary>
	<brief_title>Phase I/II Study Recombinant Human Interferon-gamma ( rIFN-gamma ) HIV-Infected Children</brief_title>
	<detailed_description>It likely infant child severely immunocompromised HIV infection would respond immunomodulators augment different portion host defense system . Interferon-gamma show benefit child severely compromise nonspecific immunity may thus benefit HIV infection . Patients treat subcutaneous rIFN-gamma 3 time week 24 week follow additional 12 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : AZT ddI therapy . PCP prophylaxis . Allowed : Antipyretics . Antiemetics . Antihistamines . Decongestants . Skin creams lotion . Immunizations accord current recommendation . Patients must : Class P2 symptomatic HIV infection . Ongoing AZT ddI therapy 6 month long duration . Exclusion Criteria Concurrent Medication : Excluded : Antiretroviral therapy AZT ddI . Chemotherapy active malignancy . Amphotericin B systemic fungal infection . Patients follow prior condition exclude : History congestive heart failure arrhythmia . History congenital heart disease . History seizure disorder require anticonvulsant medication . ( NOTE : History uncomplicated febrile seizure exclude . ) Prior Medication : Excluded within 8 week prior study entry : Immunomodulators IVIG . Prior Treatment : Excluded : Red blood cell transfusion within 4 week prior study entry . Required : Ongoing AZT ddI therapy 6 week long duration . Ongoing PCP prophylaxis 6 week duration . Ongoing alcohol drug use .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Interferon-gamma , Recombinant</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>